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Abstract
GPR56 is a member of the adhesion G protein-coupled receptor (GPCR) family. Despite the importance of GPR56 in brain
development, where mutations cause a devastating human brain malformation called bilateral frontoparietal
polymicrogyria (BFPP), the signaling mechanism(s) remain largely unknown. Like many other adhesion GPCRs, GPR56 is
cleaved via a GPCR autoproteolysis-inducing (GAIN) domain into N- and C-terminal fragments (GPR56
N and GPR56
C);
however, the biological significance of this cleavage is elusive. Taking advantage of the recent identification of a GPR56
ligand and the presence of BFPP-associated mutations, we investigated the molecular mechanism of GPR56 signaling. We
demonstrate that ligand binding releases GPR56
N from the membrane-bound GPR56
C and triggers the association of
GPR56
C with lipid rafts and RhoA activation. Furthermore, one of the BFPP-associated mutations, L640R, does not affect
collagen III-induced lipid raft association of GPR56. Instead, it specifically abolishes collagen III-mediated RhoA activation.
Together, these findings reveal a novel signaling mechanism that may apply to other members of the adhesion GPCR family.
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Introduction
Adhesion G protein-coupled receptors (GPCRs) are a family of
noncanonical seven transmembrane spanning (7TM) receptors.
There are a total of 33 members in the family in both humans and
mice, present in almost every organ system with physiological
functions in development, reproduction, immunity, neuronal and
epithelial function, as well as tumorigenesis [1]. Structurally, they
are differentiated from other subgroups of GPCRs by the presence
of an exceptionally long extracellular N-terminal region and
juxtamembrane GPCR autoproteolysis-inducing (GAIN) domain
[2–4]. Most members of the adhesion GPCRs undergo GAIN
domain-mediated autoproteolytic process at the GPCR proteolysis
site (GPS) motif to produce an N-terminal fragment and a C-
terminal fragment [4,5]. The biological significance of this
autocleavage and its implication in receptor signaling remain
largely unknown.
GPR56 is one important member of the adhesion GPCR
family, as mutations in GPR56 cause a devastating human brain
malformation called bilateral frontoparietal polymicrogyria (BFPP)
[6,7]. Additionally, GPR56 has also been reported to play a
critical role in cancer progression by regulating angiogenesis [8,9].
We recently discovered that collagen III is a ligand of GPR56 in
the developing brain and that the binding of GPR56 to collagen
III activates RhoA by coupling to Ga12/13 [10]. In the context of
cancer biology, GPR56 was shown to bind tissue transglutaminase
(TG2). Although it is unclear whether the binding of TG2 to
GPR56 triggers downstream signaling, deleting the binding site of
TG2 in GPR56 activates PKCa and elevates VEGF production in
a melanoma cell line MC-1 [8,9]. Nevertheless, the molecular
mechanism(s) underlying GPR56 signaling, including the impor-
tance of GPR56
N-GPR56
C interactions, remain poorly under-
stood.
To gain insight into GPR56 signaling, we explored the
molecular mechanism of the activation of GPR56 signaling by
collagen III using wild type GPR56 and its BFPP associated
mutants. Our results demonstrate that collagen III binding causes
the release of GPR56
N from cell surfaces and induces GPR56
C
redistribution to detergent resistant membrane fragments (DRMs),
the biochemical correlate of lipid rafts. Furthermore, L640 is an
evolutionarily conserved amino acid in GPR56 across multiple
species, and a BFPP-associated mutation at this amino acid
residue, L640R, specifically abolishes collagen III-induced RhoA
activation.
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Reagents and Antibodies
Sulfo-NHS-Biotin reagent was purchased from Pierce; Mem-
PER Eukaryotic Membrane Protein Extraction Reagent Kit was
from Thermo Scientific; Streptavidin–agarose beads from Sigma;
RIPA buffer from Boston Bioproducts; Protease inhibitor cocktail
(EDTA-free) from Roche Diagnostics; Collagen III protein was
from AbCam; Mouse GPR56 cDNA cloned into pCDNA3.1(+)
vector as described previously [11]; GPR56 mutations were
created by site-directed mutagenesis using the QuikChange II XL
Site-Directed Mutagenesis kit (Stratagene), as previously described
[12]; Cholera toxin B subunit (CTB)–Alexa Fluor 488 were
purchased from Invitrogen. Rabbit polyclonal anti-CTB antibody
was generated in the Lencer lab [13]. HRP-labeled secondary
antibodies were purchased from Sigma-Aldrich. Alexa Fluor 488
goat anti-mouse IgG (H+L) was purchase from Invitrogen. Mouse
anti-GPR56
N (CG4) was purchased from Biolegend. The mouse
anti-GPR56
N (H11) antibody was generated at the Dana Farber/
Harvard Cancer Center Monoclonal Antibody Core and the
rabbit anti-GPR56
C (199) antibody was generated at Yenzym
Antibodies, as previously described [14,15]. The GST-RBD beads
and mouse monoclonal anti-RhoA antibody were purchased from
Cytoskeleton.
Cells
SH-SY5Y cells uptake limited copy number of transgene during
in vitro transient transfection, which is more relevant to the in vivo
protein expression pattern. Therefore, we used SH-SY5Y cells for
all imaging and flow cytometry study. However, this cell line is not
suitable for analyses that require high transfection efficiency, such
as DRM fractionation, Co-IP, GTP-Rho Pull-Down Assay, and
Western blot analysis of the cell conditioned media. Thus, we used
HEK 293T cells for those assays.
Biotinylation of Cell Surface Proteins and Western Blot
Biotinylation of cell surface proteins was performed as
previously described [12]. HEK293T cells were transfected with
VSVG/His-tagged wild-type or mutant GPR56 constructs.
Biotinylated proteins were enriched with streptavidin agarose
beads, followed by western blot with standard western blot
protocol. Western blot band density in each experiment was
measured by Image QuantTL (Amersham Bioscience, Arlington
Heights, IL). Two-tailed Student’s t-tests were performed for P
values.
Membrane Protein Extraction and Co-
Immunoprecipitation (co-IP)
The membrane proteins were enriched by Mem-PER Eukary-
otic Membrane Protein Extraction Reagent Kit (Thermo Scien-
tific), following manufactory protocol. Briefly, HEK 293T cells
transfected with wild type or L640R mutant Gpr56 cDNA were
stimulated with collagen III or the vehicle (acetic acid) for 5
minutes, as described in previously [10]. About 5610
6 cells per
sample were used for membrane protein extraction. The isolated
membrane fraction samples were precleared for 1 h with protein
G Sepharose (Invitrogen), followed by incubation with rabbit anti-
GPR56
C (199) antibodies along with protein G-Sepharose. The
immune complexes were washed and eluted with Laemmli Buffer
for western blot. GPR56
N and GPR56
C proteins were detected by
mouse anti-GPR56
N (H11) and rabbit anti-GPR56C (199),
respectively.
Immunofluorescent Confocal Imaging
For cell surface staining of GPR56
N and GPR56
C, SH-SY5Y
cells were plated on Poly-d-lysin coated cover glass and were
transfected with wild type or L640R mutant Gpr56 cDNA and
cultured for 24 hr. The transfected cells were stimulated with
collagen III or acetic acid as a control for 5 min. Cells were fixed
in 2% PFA for 10 min, permeablized with 0.1% saponin for
5 min, incubated with rabbit- anti GPR56
C (199) or mouse-anti
GPR56
N (H11) antibodies visualized by rabbit Alexa-546 and
mouse Alexa-488, respectively. Images were captured by a
confocal microscope.
Lipid Raft Separation
HEK 293T cells transfected with wild type or L640R mutant
Gpr56 cDNA were incubated with 3 nM CTB for 50 minutes at
37uC, then stimulated with collagen III or the acetic acid for 5
minutes. All remaining steps were carried out on ice. Cells
(,10610
6 cells) were washed three times in ice-cold PBS and then
lysed in 500 ul ice cold DEB buffer (10 mM Tris, 150 mM NaCl
pH 7.5) containing 1% Triton X-100. Cells were homogenized
using a loose-fitting Dounce homogenizer 10 times. The homog-
enate was then passed through a 25-gauge needle 10 times. The
cell lysates were mixed with the same volume of 80% sucrose
prepared in DEB buffer and placed at the bottom of an
ultracentrifuge tube. A 5–30% linear sucrose gradient was formed
above the homogenate and centrifuged at 37,000 rpm at 4uC for
overnight in an SW41 rotor (Beckman Instruments). Fractions
were carefully removed following centrifugation, combined into
caveolin-enriched fractions. Following ultracentrifugation, gradi-
ent fractions (500 mL) were collected from top to bottom with
fraction 11 corresponding to the bottom most fraction. Aliquots of
each fraction were subjected to SDS-PAGE and western blot
analysis.
Flow Cytometry
SH-SY5Y cells were transfected with wild type or L640R
mutant Gpr56 cDNA and the transfected cells were cultured for 48
hours and followed by collagen III stimulation for 5 min. After
washing with cold PBS and blocking in 5% goat serum, 0.5%
BSA, 0.1% NaN3 in PBS and incubating for 30 min at 4uC, the
cells were incubated with mouse anti-GPR56
N antibody (CG4, 1
in 50 dilution) for 30 min at 4uC, followed by a second incubation
step with Alexa Fluor 488 goat anti-mouse IgG. The stained cells
were washed with washing buffer (0.1% BSA, 0.1% NaN3 in PBS),
and then fixed with 2% PFA. After 15 min fixation at room
temperature, cells were washed with PBS and store in PBS buffer
at 4uC until FACS. Flow cytometric analysis was performed using
a FACSCalibur (BD Biosciences) and the FlowJo software package
(Tree Star, Ashland, OR).
Detection of the Released GPR56
N in Cell Conditioned
Media
HEK 293T cells were transiently transfected with Gpr56 cDNA.
Forty eight hours later, the transfected cells were washed three
times with PBS, followed by the treatment with acetic acid or
collagen III for 5 minutes. The conditioned media were harvested,
filtered, and concentrated as previously described [12]. Equal
volume of the concentrated media were used for Western blot.
GTP-Rho Pull-Down Assay
The GTP-Rho pull-down assay was done as previously
described, using 293T cells transfected with either wild type or
L640R mutant Gpr56 cDNA [10]. The GST-RBD beads bound
Collagen III-Mediated GPR56 Signaling
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Western blotting using mouse monoclonal anti-RhoA antibody.
Results
GPR56
N Remains Associated with GPR56
C on Plasma
Membrane in Both Wild Type and Disease-causing
Mutant Proteins
Among the reported disease-associated GPR56 mutant alleles,
we have previously shown that mutations in the N-terminus of
GPR56 abolish ligand binding and mutations in the GPS motif
affect GAIN domain-mediated GPR56 protein cleavage [12,16].
To further study the mechanism of the receptor signaling, we
turned our attention to the three reported GPR56
C mutants,
E496K, R565W, and L640R (Fig. 1A) [6,7,17]. We hypothesized
that normally expressed BFPP-causing mutants could provide
insight into GPR56 signaling. In order to identify mutations that
do not affect the level of cell surface expression, we performed
biotinylation experiments. HEK293T cells transfected with wild
type or mutant GPR56 were labeled with sulfo-NHS-biotin, a
membrane impermeable biotinylation agent. Thus, only cell
surface-expressed proteins were labeled by biotin. The cells were
lysed, and all biotinylated proteins were isolated by streptavidin
affinity chromatography. Only the L640R mutant had a
comparable level of GPR56
C expression as the wild type GPR56
and was selected for further studies (Fig. 1B and C).
We performed co-IP experiments with anti-GPR56
C antibody.
As expected, GPR56
N remains associated with GPR56
C in both
wild type and L640R mutant proteins (Fig. 1D). To further verify
the association of GPR56
N and GPR56
C on the cell surface, we
performed double immunostaining with antibodies against
GPR56
N and GPR56
C, respectively. As shown in Fig. 1E, cell
surface expressed GPR56
N and GPR56
C were mostly co-localized
in both wild type and L640R mutant proteins.
Ligand Stimulation Triggers a Shift of GPR56
C from Non-
DRM to DRM Fractions in both Wild Type and L640R
Mutant GPR56
In recent decades, the original fluid mosaic model of the plasma
membrane proposed by Singer and Nichols has been challenged
[18]. Instead of a relatively continuous and homogenous fluid of
amphipathic lipids interspersed with a mosaic of proteins, it has
been found that the plasma membrane contains nanoscale
domains of sphingolipids, cholesterol, and membrane proteins,
which together form what is referred to as ‘lipid rafts’ that function
as receptor signaling platforms [19,20]. Lipid rafts are resistant to
cold nonionic detergent treatment, causing them to float to the top
fraction of isopycnic sucrose gradients; thus they are named
detergent resistant membranes (DRMs) [19–21]. Proteins that
associate with lipid rafts are defined as those that co-fractionate
with DRM fractions. Therefore, cold-detergent extraction and
Figure 1. Cell surface expression of GPR56 and its mutant protein. (A). Schematic representation of GPR56 protein with three GPR56
C
mutations indicated. (B). Detection of membrane expressed GPR56 by biotinylation experiments. Cells transfected with wild type Gpr56 and L640R
mutant cDNA have comparable cell surface expression of GPR56
C, whereas cells transfected with either E496K or R565W show much reduced or
absent cell surface expression of GPR56
C.( C). Bar graphs depict optical density of the western blot of GPR56
C in (B). (D) Analysis of the N- and C-
terminal fragment association on plasma membrane by coimmunoprecipitation (IP) experiments. The association of GPR56
N and GPR56
C was
observed in both wild type and L640R mutant receptors. (E). Detection of colocalization of GPR56
N and GPR56
C on cell plasma membrane by
immunostaining. Scale bar: 10 mm.
doi:10.1371/journal.pone.0100043.g001
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proteins associated with lipid rafts.
It was recently reported that a low level of GPR56
C is
constitutively associated with membrane lipid rafts [22]. However,
it is not known whether there is a dynamic presence of GPR56 in
the lipid raft upon ligand stimulation. We set out to test the
hypothesis that lipid raft association is required for GPR56
signaling. HEK 293T cells transfected with GPR56 cDNA were
stimulated with either collagen III or acetic acid for 5 minutes.
The cells were lysed in the presence of detergent (1% Triton X-
100) on ice and subjected to DRM fractionation. GPR56
N is
tethered non-covalently with GPR56
C on the plasma membrane,
and therefore is restrictedly present in the non-raft fractions
(Fig. 2A). Consistent with a previous report [22], we did detect a
low basal level of GPR56
C in the lipid raft fractions (Fig. 2A).
Interestingly, we observed a significant shift of GPR56
C from non-
raft to lipid raft fractions upon collagen III stimulation (Fig. 2A
and B), indicating that GPR56 probably needs lipid rafts as a
platform for its signal transduction.
To examine whether the L640R mutation affects the GPR56
C
shift to a lipid raft upon ligand stimulation, DRM analysis was
performed using this mutant receptor. Our result showed that the
mutant GPR56
C also translocated to lipid raft fractions after
ligand stimulation (Fig. 2 C and D), similar to the behavior of wild
type GPR56. This data indicated that this disease-associated C-
terminal mutation does not disrupt collagen III-induced associa-
tion of GPR56 with plasma membrane lipid nanodomains. Thus,
collagen III binds both wild type and the L640R mutant, resulting
in the C-terminal fragment associating with DRMs.
Ligand Binding Releases GPR56
N from the Membrane-
bound GPR56
C
Overexpression of GPR56
C alone enhanced RhoA activation,
suggesting that the binding of GPR56
N to GPR56
C probably
inhibits GPR56 downstream signaling [23]. Therefore, we
hypothesized that the binding of collagen III activates RhoA by
removing GPR56
N from GPR56
C. To test this hypothesis, we
transfected Gpr56 cDNA into SY5Y cells and stimulated the cells
with collagen III or acetic acid as a control for 5 minutes. The cells
were stained with antibodies against GPR56
C or GPR56
N. There
was no significant change in the level of plasma membrane wild
type or L640R mutant GPR56
C upon collagen III binding as
compared to controls (Fig. 3A, D, G, J), indicating that 5 min of
stimulation does not induce GPR56
C endocytosis. Interestingly,
membrane-bound GPR56
N was dramatically decreased upon
collagen III treatment for both wild type and the L640R mutant
(Fig. 3B, E, H, K). To quantify the reduction of cell surface
GPR56
N after collagen III treatment, we performed flow
cytometry analysis. Indeed, compared to the control and
consistent with panels A–L, collagen III stimulation caused a
significant reduction of surface GPR56
N in both wild type and
L640 mutant (Fig. 3M and N). To exclude the possibility that
GPR56
N was internalized upon binding to collagen III, we
subjected the cell conditioned media to western blot analysis. As
shown in Fig. 3O, higher level of GPR56
N was detected in
collagen III treated cell conditioned media, indicating that the
binding of collagen III releases GPR56
N from cell plasma
membrane. We have previously shown that membrane-bound
GPR56
N has lower molecular weight due to lesser degree of
glycosylation, whereas secreted GPR56
N is more heavily glycosy-
lated and therefore has higher molecular weight [12]. Interesting-
ly, collagen III treatment predominantly enriched the membrane-
bound GPR56
N (Fig. 3O).
Collagen III Stimulation does not Induce RhoA Activation
in the L640R Mutant
Thus far, L640R appears to behave like the wild type receptor
in our assays, despite the fact that it confers a deleterious null
phenotype in humans [7,24]. We therefore hypothesized that the
single amino acid change from Leucine to Arginine in the seventh
transmembrane spanning abolishes the signaling capacity of the
receptor upon ligand binding. To test this hypothesis, we
performed a RhoA activation assay. HEK 293T cells were
transfected with either wild type or L640R mutant Gpr56 cDNA.
The transfected cells were treated with either acetic acid or
collagen III for 5 minutes, followed by GTP-Rho pull-down assay
as previously described [10]. Indeed, cells transfected with L640R
mutant cDNA failed to induce RhoA activation upon ligand
stimulation, in contrast to the robust RhoA activation in cells
transfected with wild type GPR56 (Fig. 4A and B). To further
confirm that the lack of RhoA activation associated with L640R
mutant is GPR56 signaling specific, we measured RhoA activation
in cells expressing wild type or L640R upon the addition of RhoA
activator Calpeptin. L640R transfected cells demonstrated a
robust RhoA activation upon Calpeptin treatment comparable
to cells transfected with wild type GPR56 (Fig. 4C). In sum, the
BFPP-associated L640R mutation in GPR56
C abolishes GPR56
function by disrupting downstream RhoA signaling.
L640, an Evolutionarily Conserved Amino Acid Residue, is
Important for GPR56 Signaling
Crystal structures of multiple GPCRs from the rhodopsin and
secretin families have been determined [25–28]. These structures
shed light on how GPCRs are activated, and indicate that there
are major differences among the different GPCR families,
especially in the ligand binding extracellular cavity. While
structural information for the transmembrane helices of adhesion
GPCRs has yet to be determined, computational modeling of
GPR56 showed that L640 is positioned in the last transmembrane
helix close to the extracellular side (Fig. 5A). The L640 side chain
faces the extracellular cavity (Fig. 5B), which is important for
ligand interaction in the rhodopsin and secretin families of
GPCRs. Amino acid sequence alignment revealed that L640 is
evolutionarily conserved in GPR56, across multiple species, but
not so in the majority of other adhesion GPCRs family members
(Fig. 5C and Fig. 6).
Discussion
We previously showed that Collagen III is a ligand of GPR56 in
the developing brain [10,29]. Upon binding to collagen III,
GPR56 activates RhoA via coupling to Ga12/13 [10]. Here, we
discover that collagen III binding also induces release of the
GPR56
N fragment, allowing the GPR56
C fragment to associate
with DRMs (and presumably lipid rafts in vivo). Surprisingly, the
L640R mutation does not inhibit these processes, but instead
blocks downstream RhoA activation (Fig. 7).
Like most other adhesion GPCRs, GPR56 is autocatalytically
cleaved through the GPS motif between amino acids histidine-381
and leucine-382 into N- and C-terminal fragments, GPR56
N and
GPR56
C, respectively [8,12,30]. Although mutations in the GPS
domain disrupt this cleavage and cause human BFPP disease, the
biological significance of this cleavage is not entirely clear. We
previously showed that the cleaved GPR56
N remains associated
with GPR56
C at the plasma membrane [12]. Furthermore, work
from Hall’s group showed that overexpression of GPR56
C alone
results in constitutive activation of RhoA [23]. We therefore
hypothesized that the association of GPR56
N and GPR56
C keeps
Collagen III-Mediated GPR56 Signaling
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activates the receptor by removing GPR56
N from GPR56
C.
Indeed, our data show that collagen III treatment cause the
releases of GPR56
N from cell surface and the activation of RhoA.
Lipid rafts are special microdomains on the cell plasma
membrane, composed of a combination of sphingolipids, choles-
terol, and membrane proteins. These specialized membranes
mediate cellular processes by serving as organizing centers for the
assembly of signaling molecules, influencing membrane protein
Figure 2. Collagen III induces a shift of GPR56
C from the non-raft to raft fractions. (A). Western blot analysis of the lipid raft fractionation of
293T cells transfected with wild type Gpr56 using anti-GPR56
C (199), and GPR56
N (H11) to detect the C-terminal and N-terminal of GPR56,
respectively. Cholera toxin B subunit (CTB), which binds to ganglioside GM1, served as a marker for lipid raft. Different lane numbers correspond to
different fractions after sucrose gradient centrifugation. Higher protein bands in fraction 9–11 likely represent protein aggregate. Arrowhead
indicating the corresponding GPR56
C and arrow showing the responding GPR56
N.( B). The relative optical intensity of GPR56
C observed in A was
measured using Image QuantTL program and presented as mean 6 SE in a linear plot. n=3, *P=0.0124, Student t test. (C) Western blot analysis of
the lipid raft fractionation of 293T cells transfected with L640R mutant cDNA. Higher protein bands in fraction 8–11 likely represent protein
aggregate. Arrowhead indicating the corresponding GPR56
C and arrow showing the responding GPR56
N.( D). The relative optical intensity of GPR56
C
observed in C was measured using Image QuantTL program and presented as mean 6 SE in a linear plot. n=3, *P=0.006, Student t test.
doi:10.1371/journal.pone.0100043.g002
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localized signaling pathways have been reported to depend on
association with lipid rafts including those activated by EGF, IgE,
the T- and B-cell receptors, and CD40-mediated Akt phosphor-
ylation [31]. A recent report showed a dynamic residence of the
myeloid cell-specific adhesion GPCR EMR2 during signaling
[32]. In this study, we demonstrated that collagen III treatment
causes a shift of GPR56
C from non-raft to raft fractions, suggesting
that GPR56 probably signals most efficiently in these nanodo-
mains. In contrary to the previous report, we also observed a
similar shift in L640R mutant receptors upon ligand stimulation
(Fig. 3).
In vitro characterization of GPR56 indicates that various BFPP-
associated mutations disrupt its function through different
mechanisms. Mutations in the tip of GPR56
N renders the receptor
inactive by abolishing ligand binding [16,22], whereas mutations
at the GPS motif within the GAIN domain disrupt receptor
function by abolishing the GAIN domain-mediated receptor
autocleavage [12]. Previous biochemical studies have demonstrat-
ed that most disease-associated mutations reduce the surface
expression of GPR56, with the exception of the L640R mutant
that actually retains a high level of surface expression [12]. This
reinforces the reasoning that there are probably other mechanisms
responsible for the null phenotype associated with this mutation.
In this study, we discovered that L640R mutant receptor behaves
very similarly to the wild type GPR56 except in regards to collagen
III-mediated RhoA activation. One possible explanation is that the
L640R mutation disrupts coupling with Ga12/13, thereby abolish-
Figure 3. Collagen III treatment causes a reduced plasma membrane associated GPR56
N. (A–L). Immunostaining of GPR56
N and GPR56
C.
Collagen III stimulation results in a decreased level of GPR56
N.( M). Detection of surface expressed GPR56
N by flow cytometry. Surfaced expressed
GPR56
N was probed with anti- GPR56
N (CG4) antibody, followed by flow cytometry analysis. Shown are representative histograms. (N) Bar graphs
show the mean and SD of the geometric mean fluorescence intensity (MFI) of GPR56
N expression. n=3, *P=0.02, **P=0.008. (O) Western blot
detection of GPR56
N in the cell conditioned media with or without collagen III treatment. Collagen III treatment results in a higher GPR56
N in the cell
conditioned media.
doi:10.1371/journal.pone.0100043.g003
Figure 4. L640R mutation attenuates RhoA activation upon collagen III stimulation. (A) The addition of collagen III caused an increased
level of GTP-RhoA in cells transfected with wild type GPR56, but not in cells transfected with L640R mutant. Total RhoA expression in the cell lysate
served as a loading control. (B) Bar graph of the relative optical density of GTP-RhoA. n=3, *P=0.024. (C) The addition of Calpeptin resulted in a
comparable elevation of GTP-RhoA in cells transfected either wild type or L640R mutant Gpr56 cDNA.
doi:10.1371/journal.pone.0100043.g004
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PLOS ONE | www.plosone.org 6 June 2014 | Volume 9 | Issue 6 | e100043Figure 5. Position of L640 in the GPR56 transmembrane helices. (A) L640 is positioned on the transmembrane helix 7 close to the
extracellular side. Its side chain faces the extracellular cavity where ligands typically bind to in other receptor families. L640 is colored magenta. (B)
The mutation of Leucine to Arginine creates a long charged side chain that may reside in multiple conformations. The side chain of Arginine (white
and blue) is able to reach residues from other transmembrane helices and possibly be involved in new interactions that the Leucine side chain is
unable to. These interactions may favor a locked inactive conformation of the receptor. The GPR56 model was made by MODELLER based on the
secretin family structure (PDB ID: 4L6R). Nitrogen and oxygen atoms are colored blue and red, respectively. Figure was drawn by PYMOL. (C)
Alignment of the TM7 in GPR56 orthologs. ClustalW was used to perform an amino acid sequence alignment of the TM7 in GPR56 orthologs. L640 is
highly conserved among GPR56 orthologs.
doi:10.1371/journal.pone.0100043.g005
Figure 6. Alignment of TM7 in adhesion-GPCRs. ClustalW was used to perform an amino acid sequence alignment of the L640 residue in
adhesion-GPCRs. L640 is not conserved among the majority of adhesion GPCRs.
doi:10.1371/journal.pone.0100043.g006
Collagen III-Mediated GPR56 Signaling
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e100043ing RhoA signaling capabilities. As we did not directly measure
collagen III binding to the L640R mutant, it is also formally
possible that collagen III binding is compromised by this mutation,
thereby blocking RhoA signal transduction. This seems implau-
sible as collagen III treatment released GPR56
N from the
membrane-bound GPR56
C as well as triggered a shift of GPR56
C
from non-DRM to DRM fractions in both wild type and L640R
mutant GPR56.
The L640 side chain faces the extracellular cavity (Fig. 5B),
which is important for ligand interaction in the rhodopsin and
secretin families of GPCRs. Amino acid sequence alignment
revealed that L640 is evolutionarily conserved in GPR56, across
multiple species, but not so in the majority of other adhesion
GPCRs family members (Fig. 5C and Fig. 6). Taken together, it is
possible that the mutation of Leucine to an Arginine may interfere
with the activation of the receptor by creating a locked inactive
receptor. The long and charged side chain of arginine may reach
out to residues from other transmembrane helices of the receptor
and become involved in new interactions that favor an inactive
receptor conformation, abolishing the signaling ability of the
receptor (Fig. 5B). Alternatively, L640 could be critical for Ga12/13
docking to GPR56C, thereby rendering L640R incapable of
signaling via RhoA.
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